|Title:||Interstitial Lung Disease Acute Exacerbation Audit within the COVID-19 Pandemic|
|Author(s):||DBarry S Toland K Hurley|
|Institution:||Beaumont Hospital , Dublin|
|Poster:||Click to view poster|
|Abstract:||Interstitial lung disease( ILD) is a chronic progressive respiratory condition which impairs lung function and may place patients at risk of severe COVID-19 (SARS-CoV-2) infection.|
A study conducted during the first wave of the COVID-19 pandemic showed a mortality rate of 49% for patients with pre-existing ILD who contracted COVID -19 .
We conducted a single centre retrospective study of all patients admitted to Beaumont hospital during the period October 2020 to March 2021 with ILD exacerbation. We looked at their baseline demographics , pre admission therapy , as well as the cause of exacerbation and the mortality rate.
10 patients were identified who were admitted during this period . Seven (70%) were male with a mean age of 72. (Standard deviation) .Nine patients (90%) were treated with antibiotics during their admission while only two (20%) of these had a confirmed isolated pathogen . There was a 30% all -cause mortality rate in the group study net , with one of these having tested positive for COVID -19 prior to their death .
The audit demonstrates a similarly high mortality rate for patients requiring admission to hospital with an exacerbation of ILD .